Parkinson's Disease Treatment Market Reviewed in New Report Recently Published by MarketPublishers.com

04 Nov 2011 • by Natalie Aster
Parkinson's Disease Treatment Market Reviewed in New Report Recently Published by MarketPublishers.com

LONDON – What are the commercial prospects for the treatment of Parkinson's disease?  What exact revenue predictions are there for Parkinson's disease treatments at total world, submarket, product and national levels to 2021? How can the drugs Stalevo/Comtess, Sifrol, Azilect and Requip perform through 2021?

New market research studyParkinson's Disease: World Drug Market 2011-2021prepared by Visiongain has been recently published by Market Publishers Ltd. It covers hot issues on the market for Parkinson’s disease treatment. The study opens up quantitative and qualitative analysis on the market, offer key understanding of the market development and provides in-depth comprehensive forecasts including revenue projections.

Report Details:

Title: Parkinson's Disease: World Drug Market 2011-2021
Published: September, 2011
Pages: 142
Price: US$ 2,664

Report Contents:

1. EXECUTIVE SUMMARY
1.1 Parkinson's Disease: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods


2. PARKINSON'S DISEASE IN 2011: A SCIENTIFIC AND CLINICAL OVERVIEW
2.1 Parkinson's is Characterised by Dopamine Depletion
2.2 Motor Symptoms of Parkinson's Disease
  2.2.1 Tremor
  2.2.2 Rigidity
  2.2.3 Bradykinesia
  2.2.4 Postural Instability
  2.2.5 Other Motor Symptoms
2.3 Cognitive, Behavioural and Other Symptoms
  2.3.1 Cognitive Deficits
  2.3.2 Behavioural and Mood Difficulties
  2.3.3 Other Symptoms
2.4 Subtypes and Possible Origin of the Disease
2.5 Timeline of Parkinson's Disease Treatment


3. THE GLOBAL MARKET FOR PARKINSON'S DISEASE DRUGS 2011-2021
3.1 The Parkinson's Disease Market: Overview 2011-2021
3.2 The Parkinson's Disease Market: Breakdown 2011-2021
3.3 Dopaminergic Agents: Still Key to the Market
  3.3.1 Dopaminergic Agents: Market Forecast 2011-2021
3.4 Dopamine Agonists: The Foremost Commercial Class of Parkinson's Drugs
  3.4.1 Dopamine Agonists: Market Forecast 2011-2021
3.5 COMT Inhibitors: The Best-Selling Class in the Parkinson's Drug Market
  3.5.1 COMT Inhibitors: Market Forecast 2011-2021
3.6 MAO Inhibitors: The Fastest-Growing Market Sector
  3.6.1 MAO Inhibitors: Market Forecast 2011-2021
3.7 Other Classes of Parkinson's Disease Treatment
  3.7.1 Other Classes of Parkinson's Disease Treatment: Market Forecast 2011-2021


4. LEADING PRODUCTS IN THE PARKINSON'S DISEASE TREATMENT MARKET
4.1 Four Drugs Lead the Market
4.2 Stalevo and Comtess (Orion/Novartis)
  4.2.1 Stalevo and Comtess: Sales Forecast 2011-2021
4.3 Sifrol (Boehringer Ingelheim)
  4.3.1 Sifrol: Sales Forecast 2011-2021
4.4 Azilect (Teva Pharmaceuticals)
  4.4.1 Azilect: Sales Forecast 2011-2021
4.5 Requip (GlaxoSmithKline)
  4.5.1 Requip: Sales Forecast 2011-2021
4.6 Other Products
  4.6.1 Other Products: Market Forecast 2011-2021


5. LEADING NATIONAL MARKETS FOR PARKINSON'S TREATMENTS 2011-2021
5.1 The US is the Largest Market
5.2 The US: Market Forecast 2011-2021
5.3 The EU5: Market Forecasts 2011-2021
5.4 Japan: Market Forecast 2011-2021
5.5 China: Market Forecast 2011-2021
5.6 India: Market Forecast 2011-2021
5.7 Rest of the World: Market Forecast 2011-2021


6. PARKINSON'S DISEASE TREATMENTS: R&D PIPELINE ANALYSIS 2011
6.1 There are More than 300 Late-Stage Trials of Parkinson's Drugs in Progress in 2011
6.2 KW-6002 (Kyowa Hakko Kirin) and Other Adenosine Receptor Antagonists
6.3 Safinamide (Merck Serono): Both Dopaminergic and Non-dopaminergic Effects?
6.4 Fipamezole (Santhera Pharmaceuticals)
6.5 Coenzyme Q10 (National Institute of Neurological Disorders and Stroke [NINDS], and Others)
6.6 Potential Gene Therapies
6.7 CERE-120 (Ceregene): Lead Gene-Therapy Product
6.8 Neurologix: Another Gene Therapy Candidate
6.9 Possible Disease-Modifying Treatments


7. TOP COMPANIES IN THE PARKINSON'S DISEASE TREATMENTS MARKET 2011
7.1 Boehringer Ingelheim
7.2 Novartis
7.3 Orion
7.4 Teva Pharmaceutical Industries
7.5 GlaxoSmithKline
7.6 Impax Laboratories
7.7 Kyowa Hakko Kirin
7.8 Merck Serono
7.9 Newron

More new market research reports by the publisher can be found at Visiongain page.

 

CONTACTS

The Market Publishers, Ltd.

Mrs. Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com